To validate a non-TF target, we treated various cell lines representing different AML subtypes with the DUSP inhibitor BCI (Figure S2J) and showed that it is an efficient inhibitor of cell growth, albeit not in a FLT3-ITD+ AML-specific fashion. This evidence concerns the gene FLT3 and acute myeloid leukemia.